ArticleScientific data2023
Plasma metabolomics profiling of 580 patients from an Early Detection Research Network prostate cancer cohort.
Article in Scientific data, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Cholesterol-lowering effects of oats induced by microbially produced phenolic metabolites in metabolic syndrome: a randomized controlled trial.Nature communications · 2026Trial
- Fibrinogen-associated plasma metabolites and implications for coagulation, inflammation, and vascular diseases.Journal of thrombosis and haemostasis : JTH · 2026Article
- Genetic architecture and analysis practices of circulating metabolites in the NHLBI Trans-Omics for Precision Medicine Program.American journal of human genetics · 2025Article
- DSCC: disease subtyping using spectral clustering and community detection from consensus networks.Briefings in bioinformatics · 2025Article
- Liquid biopsy-based multi-cancer early detection: an exploration road from evidence to implementation.Science bulletin · 2025Review
- In-depth profile of biosignatures for T2DM cohort utilizing an integrated targeted LC-MS platform.Scientific data · 2025Article
- A Comparative Study of Network-Based Machine Learning Approaches for Binary Classification in Metabolomics.Metabolites · 2025Article
- Identification of Secondary Metabolites by Multi-Omics Methods.Metabolites · 2024Article
- Fair Data, Bayesian Statistics and Human Cohort Studies: Current Trends in Metabolomic Research.Metabolites · 2024Article
- Plasma metabolomics profiling of 580 patients from an Early Detection Research Network prostate cancer cohort.Scientific data · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
Prostate cancer is the second most common cancer in men and affects 1 in 9 men in the United States. Early screening for prostate cancer often involves monitoring levels of prostate-specific antigen (PSA) and performing digital rectal exams. However, a prostate biopsy is always required for definitive cancer diagnosis. The Early Detection Research Network (EDRN) is a consortium within the National Cancer Institute aimed at improving screening approaches and early detection of cancers. As part of this effort, the Weill Cornell EDRN Prostate Cancer has collected and biobanked specimens from men undergoing a prostate biopsy between 2008 and 2017. In this report, we describe blood metabolomics measurements for a subset of this population. The dataset includes detailed clinical and prospective records for 580 patients who underwent prostate biopsy, 287 of which were subsequentially diagnosed with prostate cancer, combined with profiling of 1,482 metabolites from plasma samples collected at the time of biopsy. We expect this dataset to provide a valuable resource for scientists investigating prostate cancer metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.